SCHEMBL2858065

SCHEMBL2858065

O=C(Nc1ccc2[nH]nc(-c3cccc(F)c3)c2c1)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
NPY5R Q15761 1/20 0.51
DYRK1A Q13627 3/20 0.49
CLK2 P49760 2/20 0.49
CLK3 P49761 2/20 0.49
ROCK2 O75116 1/20 0.49
ROCK1 Q13464 1/20 0.49
LRRK2 Q5S007 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
NTRK1 P04629 1/20 0.46
TTK P33981 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
PDPK1 O15530 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
AURKA O14965 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372624 0.89 SMN1; SMN2 (0.60) SMN1; SMN2NPY5RDYRK1ACLK2CLK3
SCHEMBL2870409 0.82 JAK2 (0.56) DYRK1ACLK2ROCK1LRRK2KDM4E
SCHEMBL27558704 0.80 TTK (0.56) LRRK2NTRK1TTKPDPK1AURKA
SCHEMBL1663544 0.78 CLK2 (0.54) SMN1; SMN2DYRK1ACLK2CLK3LRRK2
SCHEMBL13811362 0.78 NTRK1 (0.46) DYRK1ACLK2CLK3LRRK2NTRK1
SCHEMBL20237020 0.78 SMN1; SMN2 (0.68) SMN1; SMN2NPY5RNPC1RAB9AALDH1A1
SCHEMBL13742747 0.75 AURKA (0.56) NTRK1TTKPDPK1AURKA
SCHEMBL2859988 0.75 ITK (0.57) DYRK1ACLK2CLK3LRRK2NTRK1
SCHEMBL2862072 0.74 DYRK1A (0.59) DYRK1A
SCHEMBL2858874 0.74 NPC1 (0.61) SMN1; SMN2NPC1RAB9ANTRK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885NPY5R 984/4885DYRK1A 1216/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 SMN1; SMN2 4781/4885NPY5R 1161/4885DYRK1A 2459/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885NPY5R 984/4885DYRK1A 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.